TRVI — Trevi Therapeutics Inc
NASDAQ · Healthcare · Biotechnology
$16.57
+$0.00 (+0.00%)
Trevi Therapeutics Inc (TRVI) is a biotechnology company listed on NASDAQ. It is led by Jennifer L. Good, based in 195 Church Street, New Haven, CT, United States, 06510, with about 34 employees. Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Net income was -$11.8M. TRVI currently screens at market cap $2.32B.
Use this TRVI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TRVI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TRVI SEC filings page. Lician reads the product cache first so this HTML stays unique to Trevi Therapeutics Inc even when a live quote feed is slow.
About Trevi Therapeutics Inc
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
TRVI Key Statistics
Market Cap
$2.32B
Volume
1.21M
Previous Close
$17.95
Day Range
$17.42 – $18.00
P/B Ratio
13.50
EPS
-$0.47
Revenue
$0.00
Net Income
-$47.91M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
34
TRVI Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$47.91M | -$29.07M | -$29.15M | -$33.94M |
| EPS (Diluted) | -$0.47 | -$0.29 | -$0.45 | -$1.49 |
Total Assets
$110.90M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$34.10M
Operating Cash Flow
-$38.26M
Free Cash Flow
$0.00
Trevi Therapeutics Inc Company Information
- Co-Founder, CEO, President, & Director
- Jennifer L. Good
- Headquarters
- 195 Church Street, New Haven, CT, United States, 06510
- Website
- www.trevitherapeutics.com
- Phone
- 203 304 2499
- IPO / Founded
- 2019-05-07
- Sector
- Healthcare
- Industry
- Biotechnology